Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases

Fig. 3

UC-MSCs’ characteristics after pro-inflammatory priming. A UC-MSCs’ morphology; B UC-MSCs’ size (µm); C DT (h) (left) and PD (right); and D UC-MSCs’ immunophenotype at basal state (NT) and after pro-inflammatory treatment by IFNγ, TNFα, IFNγ + TNFα, IL6, IL1β, GM-CSF and Mix. NA: Not applicable. n = 3 batches from 1 UC

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512